INFAI at the BSG Annual Meeting in Birmingham 2022
INFAI will participate in the BSG (British Society of Gastroenterology) Annual Meeting in Birmingham,...
Current studies
INFAI is currently conducting the following clinical studies
Study PPI; Eudra CT Number: 2017-001369-25
The Sensitivity and Specificity in Helicobacter Pylori Positive and Negative Patients with Dyspesia Taking Proton Pump Inhibitors. Sponsor: INFAI
Study: Gastromotal; Eudra CT Number: 2011-002782-38
Gastromotal 1-¹³C-Caprylic Acid breath test in the diagnosis and evaluation of therapeutic outcome in patients with dyspeptic symptoms and delayed emptying. Sponsor: INFAI
Study HEAT; Eudra CT Number: 2011-003425-96
Helicobacter eradication to prevent ulcer bleeding in aspirin users: a large simple randomised controlled trial (HEAT). Sponsor: University of Nottingham
Serialization
Implementing the EU’s Falsified Medicines Directive – new line of INFAI packaging
The EU’s Falsified Medicines Directive (2011/62/EU) has been in force since February 9, 2019. The directive is expected to protect the well-being of patients by putting an end to the criminal counterfeiting of medicine.
The Falsified Medicines Directive affects all medicinal products available on prescription.
To implement the directive, the outer packaging of every product shall be furnished with a certificate of authenticity. For the Helicobacter Test INFAI®, this certificate of authenticity is guaranteed by the cellophane wrapping around the single test sampling tubes, and the safety seal on packaging intended for hospital use.
To implement the Falsified Medicines Directive, INFAI has furnished its line of packaging with the latest technology. That way, INFAI can apply all the required safety features, including individual serial numbers, in high quality, and to transmit all the necessary data to the databases of the national verification systems. Thanks to these measures, we can guarantee patients the highest possible level of protection against counterfeits of our products.
